Cerenome expects Q3 CNSide gross billings of $1.55 million

Cerenome projected Q3 2026 CNSide gross billings of USD 1.55 million from 222 tests at list prices and an annualized Q4 2026 run rate of about USD 10 million to USD 12 million, with Medicare pricing for PLA code 0640U targeted to take effect Jan. 1, 2027.